Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 Grams
Price: Negotiable
Packaging Details: 1~10 KG Aluminum Foil Bag, 25KG/drum
Delivery Time: 1-3 working day
Payment Terms: L/C, L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Storage: |
Store In A Cool, Dry Place |
Molecular Formula: |
C13H19N3O7 |
Shelf Life: |
2 YEARS |
Molecular Weight: |
329.31 |
Product Name: |
Molnupiravir (EIDD-2801) |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Storage: |
Store In A Cool, Dry Place |
Molecular Formula: |
C13H19N3O7 |
Shelf Life: |
2 YEARS |
Molecular Weight: |
329.31 |
Product Name: |
Molnupiravir (EIDD-2801) |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Molnupiravir is an antiviral drug that has gained attention for its potential to treat viral infections, particularly in the context of the COVID-19 pandemic. Molnupiravir has shown broad-spectrum antiviral activity against various RNA viruses, including coronaviruses. Since FIP is caused by a coronavirus, there is a theoretical basis for investigating whether Molnupiravir could inhibit the replication of the virus responsible for FIP.
There are several factors to consider when exploring the use of Molnupiravir for FIP treatment. These include the severity of the disease, the stage at which the cat is diagnosed, potential side effects, and the cost-effectiveness of treatment. Additionally, FIP can manifest in various forms, including wet (effusive) and dry (non-effusive) forms, which may influence treatment strategies.
Product Name | Molnupiravir (EIDD-2801) |
Grade Standard | Pharmaceutical Grade |
Assay | 99.9% |
Apperance | White Powder |
Service | Worldwide |
Shelf Life | 2 YEARS |
Molecular Formula | C13H19N3O7 |
Test | HPLC |
Storage | Store In A Cool, Dry Place |
1. COVID-19 Treatment: Molnupiravir has been investigated as a potential treatment for COVID-19. Clinical trials have shown that it may reduce the viral load and alleviate symptoms in patients with mild to moderate COVID-19. It could be particularly useful in early-stage infections to prevent disease progression.
2. Treatment of Viral Infections: Molnupiravir has shown promise in treating a variety of RNA virus infections, including influenza viruses, coronaviruses (such as SARS-CoV-2), respiratory syncytial virus (RSV), and others. Its broad-spectrum antiviral activity makes it a candidate for treating a range of viral illnesses.
3. Prevention of Viral Transmission: Molnupiravir could be used as a prophylactic treatment to prevent viral transmission in individuals at high risk of exposure to certain viruses, such as healthcare workers or close contacts of infected individuals.